Compare Applied Materials, Inc. (AMAT) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Applied Materials, Inc. vs Quest Diagnostics Inc — how do they compare? Applied Materials, Inc. trades at $580.64 (market cap $478.36B), while Quest Diagnostics Inc trades at $207.44 (market cap $22.96B). The key difference: Applied Materials, Inc. is far larger — about 20.8× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays the higher dividend (1.66%). Which is the better fit depends on your goals.
| AMAT | DGX | |
|---|---|---|
Market Cap | $478.36B | $22.96B |
Sector | Technology | Health |
52-Week High | $723.00 | $216.02 |
52-Week Low | $156.25 | $166.42 |
Enterprise Value | $477.39B | $28.98B |
Dividend Yield | 0.35% | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Applied Materials (AMAT) trades at $602.50, up 2.35% today, with strong earnings beats in recent quarters and a consensus analyst price target of $644.33. The stock shows a bullish moving average signal but neutral oscillators, with key resistance at $617 and support at $573. Revenue grew to $28.37B in 2025, with a net income margin of 24.66%, though valuation ratios like P/E of 56.68 are elevated. Recent news highlights CEO Gary Dickerson's optimism on AI-driven semiconductor demand, positioning AMAT for multi-year growth.
The outlook for AMAT is positive, driven by AI infrastructure expansion and consistent earnings outperformance. Risks include high valuation multiples and semiconductor cycle volatility. With 76.9% of analysts rating it a buy and institutional sentiment bullish, the stock offers growth potential but requires monitoring of execution and market conditions.
Quest Diagnostics (DGX) trades at $207.44, down 0.29% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported $11.04B revenue in 2025 with a 9.08% net margin, supported by strong cash flow from operations of $1.89B. Recent news highlights expansion of oncology testing services, including New York State approval for Haystack MRD, enhancing its diagnostic portfolio.
DGX offers steady growth with a consensus price target of $226, implying 9% upside. Risks include rising debt levels and healthcare policy uncertainties, but analyst sentiment leans positive with 38% buy ratings. The stock's valuation at a P/E of 22.92 appears reasonable given its profitability and market position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Applied Materials, Inc.
Applied Materials is the world's largest supplier of semiconductor manufacturing equipment, providing materials engineering solutions to help make nearly every chip in the world. The firm's systems are used in nearly every major process step with the exception of lithography. Key tools include those for chemical and physical vapor deposition, etching, chemical mechanical polishing, wafer- and reticle-inspection, critical dimension measurement, and defect-inspection scanning electron microscopes.
Read more on AMAT →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
